Which vaccine is used to prevent pneumococcal disease in an 18-month-old child with bronchopulmonary dysplasia?

Which vaccine is used to prevent pneumococcal disease in an 18-month-old child with bronchopulmonary dysplasia?

• A. PCV7
• B. PCV13
• C. PCV23
• D. PCV33

Answer: (B)

The key idea is that young children with chronic lung disease need a pneumococcal vaccine that elicits a strong, lasting immune response. Conjugate pneumococcal vaccines do this by linking the bacterial capsule polysaccharide to a protein, which helps the immature immune system recognize the threat and form memory. In an 18-month-old, the vaccine that provides broad protection against many serotypes and is routinely used in early childhood is the 13-valent conjugate vaccine. It covers more serotypes than the older 7-valent version and is the standard choice for this age and risk group. The 23-valent vaccine is a polysaccharide formulation and is less immunogenic in children under 2, and is typically reserved for older children or adults with specific risk factors after age 2. A non-existent or outdated 33-valent option isn’t part of the current schedule. So the best choice for an 18-month-old with bronchopulmonary dysplasia is the PCV13 conjugate vaccine, offering robust protection during a vulnerable period.

The key idea is that young children with chronic lung disease need a pneumococcal vaccine that elicits a strong, lasting immune response. Conjugate pneumococcal vaccines do this by linking the bacterial capsule polysaccharide to a protein, which helps the immature immune system recognize the threat and form memory. In an 18-month-old, the vaccine that provides broad protection against many serotypes and is routinely used in early childhood is the 13-valent conjugate vaccine. It covers more serotypes than the older 7-valent version and is the standard choice for this age and risk group.

The 23-valent vaccine is a polysaccharide formulation and is less immunogenic in children under 2, and is typically reserved for older children or adults with specific risk factors after age 2. A non-existent or outdated 33-valent option isn’t part of the current schedule. So the best choice for an 18-month-old with bronchopulmonary dysplasia is the PCV13 conjugate vaccine, offering robust protection during a vulnerable period.